Ferdinandos Skoulidis (@FSkoulidis) ranks #19 among US lung cancer KOLs on X in 2026, by engagement from fellow physicians. 16 physicians shared, quoted or replied to their posts this year. CMS Open Payments lists $45,431 in 2025 general payments. This profile tracks their 2026 rankings and the physicians who amplify them on X.
At a Glance
- 4 colleague posts sharing slides from Ferdinandos Skoulidis's presentations
- Lung Cancer: US #19, Global #43 · 16 physicians engaged
- Presented at ESMO 2026, ASCO 2026 in 2026
- CMS Open Payments lists $45,431 in 2025 general payments.
This Month
What Ferdinandos Skoulidis has posted in the last 30 days. Updated November 10, 2026.
No trial posts in the last 30 days.
2026 Rankings
| List | US rank | Global rank | Physicians engaged | Physician engagements | |
|---|---|---|---|---|---|
| Lung Cancer | #19 | #43 | 16 | 19 | Full ranking |
From the Podium, 2025–26
Talks, posters and sessions Ferdinandos Skoulidis presented at SABCS 2025 and 2026 meetings, each confirmed by a public source.
- ESMO 2026 · Late-breaking abstract (LBA5), Presidential Symposium IIKrascendo 1: Efficacy and Safety of Divarasib vs Sotorasib or Adagrasib in Previously Treated Locally Advanced or Metastatic KRAS G12C-Mutated NSCLC
- ASCO 2026 · Clinical Science Symposium (8510)Krascendo-170: 1L Divarasib + Pembrolizumab in Advanced KRAS G12C+ NSCLCSource: @HHorinouchi on X ↗
- ASCO 2026 · Rapid oral (8515)TRITON: Tremelimumab + Durvalumab + CT vs Pembrolizumab + CT in 1L NSQ mNSCLC with STK11/KEAP1/KRAS MutationsSource: @HHorinouchi on X ↗
What Colleagues Are Saying About Ferdinandos Skoulidis
2026 posts by fellow physicians that mention @FSkoulidis, quoted word for word.
Dr. @FSkoulidis #ASCO26: Krascendo 170 - first-line divarasib + pembrolizumab in KRAS G12C NSCLC. In PDL1+, RR 73%, mPFS 19.3m! In PDL1-, unconfirmed RR 70%. Impressive efficacy and DCR. https://t.co/p4TZP4y3sL
New standard of care for KRAS G12C mutation positive NSCLC. @FSkoulidis presents Krascendo-1 head to head trial of divarasib vs sotorasib or adagrasib- convincing improving PFS (9.8 m vs 5.7 m, HR 0.58) and OS (17.7m vs 12.0m, HR 0.58) https://t.co/6sxEHeDjAq
#ASCO26 #TRITON @FSkoulidis I’m struggling to understand the value of highlighting secondary endpoints while the primary endpoint remains blinded. The reported improvements in ORR and DoR for tremelimumab + durvalumab + chemotherapy versus pembrolizumab + chemotherapy are numerical rather than compelling, and small patient numbers. Without the 1ry endpoint, it is impossible to know whether these findings represent a meaningful clinical advance or simply noise. Let’s wait for the study to read out before drawing conclusions. #NSCLC #LCSM
🆙 #ASCO26 #LCSM Rapid Oral 🔥TRITON: Tremelimumab + durvalumab + CT vs pembro + CT in 1L NSQ NSCLC with STK11, KEAP1, and/or KRAS mut ✅ORR 39% vs 34.9% ✅KRAS: ORR 48% vs 33.3% 🎙️ @FSkoulidis 🔢8515 ☑️NCT06008093 🔗 https://t.co/FutGF2Nz3A @OncoAlert @Larvol @ASCO @IASLC @KRASKickers
Is there a ‘new diva’ in KRAS G12C lung cancer? Our @FSkoulidis @UTMDAnderson reviews phase Ib KRAScendo-170 1L chemo-free divarasib + pembrolizumab in KRAS G12C+ mNSCLC ▫️PD-L1+ cohort: ORR 72.9% ▫️mPFS 19.3 mos ▫️Responses seen regardless of KEAP1/STK11 status #ASCO26 https://t.co/sBPB6tzsTW
Practice-changing KRAS G12C data! @Fskoulidis presents Krascendo 1 Ph.III: divarasib vs sotorasib/adagrasib in pretreated NSCLC. PFS 9.8 vs 5.7 mo (HR 0.58; p<0.0001). OS 17.7 vs 12.0 mo (HR 0.56; p=0.0005). ORR 58% vs 32%. #ESMO26 #LungCancer @myESMO @OncoAlert https://t.co/eAk2Th9t3a
Ferdinandos Skoulidis’s Presentations
Slides from Ferdinandos Skoulidis’s 2026 presentations, as shared by physicians in the audience.
New standard of care for KRAS G12C mutation positive NSCLC. @FSkoulidis presents Krascendo-1 head to head trial of divarasib vs sotorasib or adagrasib- convincing improving PFS (9.8 m vs 5.7 m, HR 0.58) and OS (17.7m vs 12.0m, HR 0.58) https://t.co/6sxEHeDjAq
Practice-changing KRAS G12C data! @Fskoulidis presents Krascendo 1 Ph.III: divarasib vs sotorasib/adagrasib in pretreated NSCLC. PFS 9.8 vs 5.7 mo (HR 0.58; p<0.0001). OS 17.7 vs 12.0 mo (HR 0.56; p=0.0005). ORR 58% vs 32%. #ESMO26 #LungCancer @myESMO @OncoAlert https://t.co/eAk2Th9t3a
Let’s start the 2nd Plenary @myESMO at #ESMO26 with KRASCENDO-1: divarasib raises the bar in KRAS G12C-mutated NSCLC! @FSkoulidis presents the phase III KRASCENDO-1 trial (N=338), comparing divarasib vs sotorasib or adagrasib in previously treated KRAS G12C-mutated NSCLC. Primary endpoint – PFS: • 9.8 vs 5.7 months • HR 0.58 (95% CI 0.44–0.76), p<0.0001 • 12-month PFS: 43.9% vs 24.0% Key secondary endpoint – OS: • 17.7 vs 12.0 months • HR 0.56 (95% CI 0.41–0.78), p=0.0005 • 12-month OS: 67.1% vs 49.2% My take: Impressive results! Not just improved PFS, but a substantial OS benefit against active KRAS G12C inhibitors. New SOC in this setting #ESMOAmbassadors #ESMO26 #KRASG12C #NSCLC #LungCancer #PrecisionOncology
✨ PRACTICE CHANGING ✨ data from #ESMO26 Divarasib becomes the NEW Standard of Care for 2L KRAS G12C #LungCancer @FSkoulidis presents results from Krascendo 1 Divarasib significantly prolongs PFS and OS with a more tolerable safety profile https://t.co/JAcDUqlyDi
Industry Payments
CMS Open Payments · 2025 general payments
$45,431 across 38 payments